Shanghai Key Laboratory of Genocologic Oncology

June 24, 2022 Share:

Shanghai Cancer Institute (hereinafter referred to as "SCI") was established in 1958 and is affiliated to the Shanghai Jiao Tong University School of Medicine. In 1980, it was recognized as the World Health Organization's Cooperative Center for Cancer Prevention and Control. In 1985, it was authorized to found the State Key Laboratory of Oncogenes and Related Genes. SCI set up the gene therapy research pilot test base in Shanghai together with Shanghai Municipal Commission of Science and Technology in 1996 and co-founded the SJTU Cancer Institute with SJTU in 2003. In 2010, SCI was merged with Ren Ji Hospital to form “a unity”. In 2019, the subordination of SCI was transferred to the Shanghai Municipal Education Commission, and SCI was jointly managed by SJTU School of Medicine and Ren Ji Hospital since then. At present, SCI has a total of 26820 square meters of laboratory space located in three areas, including 7820 square meters of space in Xietu Road in Xuhui District, 16000 square meters of space in Ren Ji Hospital in Pudong New Area and 3000 square meters of space in SJTU in Minhang District. There are 16 research groups and 8 youth research groups focusing on cancer microenvironment research, cancer molecular pathology, cancer epidemiology, etc. In addition, auxiliary departments such as public research platforms, editorial office of Tumor, etc. have been set up to support scientific research. By the end of 2021, there are 150 officially budgeted employees, including 132 scientific researchers, one member of the Chinese Academy of Engineering, one tenured professor and one Changjiang scholar. 30 of them hold a senior professional and technical title, and 93 of them hold a doctoral degree. There are 32 postgraduate supervisors (21 doctoral supervisors and 11 master’s supervisors), and the enrollment programs include oncology, biochemistry and molecular biology, pathogenic biology, etc. SCI has won a collection of national and Shanghai municipal talent awards at all levels, including National Distinguished Young Scholars, National Excellent Youth, National New Century Millions of Talents Project, National Ten Thousand Talents Plan, New Century Talent Plan of the Ministry of Education, Shanghai Outstanding Academic Leaders Plan, Shanghai Excellent Academic/Technology Research Leader Program, Shanghai Dawn Scholars and Shanghai Oriental Scholars, etc.The current research work of SCI is mainly oriented toward the epidemiology and etiology of malignant cancer, cancer pathogenesis and cancer cell immunotherapy, as well as research fields related to the exploration of new ways of cancer prevention and treatment. Multiple high-tech research platforms and experimental animal research platforms have been established to facilitate researches on cancer stem cells, cancer microenvironment, cancer targeted biotherapy, cancer molecular pathology, cancer immunomodulation, etc. Fully armed with advanced research equipment such as mass spectrometer, high-throughput sequencer, laser confocal microscope, small animal live imager, small animal SPECT, etc., SCI provides experimental equipment and services as well as experimental animals to both internal and external users. Since the “13th Five Year Plan” period, SCI has gained rapid development. By integrating the institute with hospitals and improving the scientific research innovation mechanism, SCI has shown significantly enhanced ability of independent innovation and continuous research outputs with a number of high-impact research achievements having been produced successively.Research projects and Awards for scientific achievements: 295 new vertical scientific research projects (including 80 national level projects) have been launched with a 95.86-million increase in funding support for scientific research. Among these projects, there are one Key Program for International (regional) S&T Cooperation Projects of China, one State Key Program of National Natural Science of China, and five new National Science and Technology Major Projects and National Key R&D Program sub-topics of the Ministry of Science and Technology of China. In recent years, SCI has maintained a steady growth in the funding support from NSFC, with 80 more new NSFC projects and 39.89 million more of NSFC project funds approved, under increasingly intensified competition by taking advantage of its advanced basic research in oncology, exploiting the potential of young researchers and enhancing the competitivity of our research projects.